首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >MicroRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics
【24h】

MicroRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics

机译:MicroRNA表达谱可识别具有不同临床生物学特征的套细胞淋巴瘤亚型

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: microRNAs (miRNA) are posttranscriptional gene regulators that may be useful as diagnostic and/or prognostic biomarkers. We aim to study the expression profiles of a high number of miRNAs and their relationship with clinicopathologic and biologic relevant features in leukemic mantle cell lymphomas (MCL). Experimental Design: Expression profiling of 664 miRNAs was investigated using a high-throughput quantitative real-time PCR platform in 30 leukemic MCLs. Statistical and bioinformatic analyses were conducted to define miRNAs associated with different clinicopathologic parameters. Gene expression profiling was investigated by microarrays in 16 matching cases to study the potential genes and pathways targeted by selected miRNAs. The prognostic value of miR-34a was investigated in 2 independent series of 29 leukemic and 50 nodal MCLs. Results: Robust consensus clustering defined 2 main MCL subgroups with significant differences in the immunoglobulin (IGHV) mutational status, SOX11 expression, genomic complexity, and nodal clinical presentation. Supervised analyses of IGHV and SOX11 categories identified 17 and 22 miRNAs differentially expressed, respectively. Enriched targets of these miRNAs corresponded to relevant pathways in MCL pathogenesis such as DNA stress response, CD40 signaling, and chromatin modification. In addition, we found 7 miRNAs showing prognostic significance independently of IGHV status and SOX11 expression. Among them, miR-34a was also associated with poor prognosis in 2 independent series of leukemic and nodal MCL, and in cooperation with high expression of the MYC oncogene. Conclusion: We have identified miRNAs and target pathways related to clinical and biologic variants of leukemic MCL, and validated miR-34a as a prognostic marker in MCL.
机译:目的:microRNA(miRNA)是转录后基因调节剂,可用作诊断和/或预后生物标志物。我们旨在研究白血病套细胞淋巴瘤(MCL)中大量miRNA的表达谱及其与临床病理和生物学相关特征的关系。实验设计:使用高通量定量实时PCR平台在30个白血病MCL中研究了664个miRNA的表达谱。进行统计和生物信息学分析以定义与不同临床病理参数相关的miRNA。在16个匹配的病例中,通过微阵列研究了基因表达谱,以研究被选定miRNA靶向的潜在基因和途径。在29个白血病和50个淋巴结MCL的2个独立系列中研究了miR-34a的预后价值。结果:强大的共有性聚类定义了2个主要的MCL亚组,在免疫球蛋白(IGHV)突变状态,SOX11表达,基因组复杂性和淋巴结临床表现方面存在显着差异。 IGHV和SOX11类别的监督分析分别鉴定了17和22个差异表达的miRNA。这些miRNA的富集靶标对应于MCL发病机理中的相关途径,例如DNA应激反应,CD40信号传导和染色质修饰。此外,我们发现了7个miRNA,它们独立于IGHV状态和SOX11表达而具有预后意义。其中,miR-34a还与2个独立的白血病和淋巴结性MCL系列预后不良以及MYC癌基因的高表达有关。结论:我们已经鉴定了与白血病MCL临床和生物学变异有关的miRNA和靶途径,并验证了miR-34a作为MCL的预后标志物。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号